AnticancerPositive observation
Record detail YSL by itself exhibits limited anticancer activity, with an IC50 value of 4.34 mM (Figure S20).
- Measure
- other
- Value
- 4.34 mM
- Target
- MCF-7
- Assay
- Not reported by source
Source publication
Artificial Tyroserleutide Transporters for Synergistic Cancer Therapy.
JACS Au · 2025
- Sequence status
- reported
- Standardization
- Sequence ready
- Source location
- text
- Activity records
- 5
Sequence evidence
Reported molecular identity
YSL
YSL
Resolved peptide links
Experimental observations
Records linked to this mention
AnticancerPositive observation
Record detail in the presence of 4.0 μM 5F–C12, the anticancer activity of YSL was remarkably potentiated, lowering the IC50 to 0.27 mM, corresponding to an improvement of 16.1-fold.
- Measure
- other
- Value
- 0.27 mM
- Target
- MCF-7
- Assay
- Not reported by source
AnticancerAntibacterialPositive observation
Record detail YSL treatment resulted in moderate suppression of approximately 36.4%.
- Measure
- percent_inhibition
- Value
- approximately 36.4%
- Target
- MCF-7
- Assay
- Not reported by source
AnticancerAntibacterialPositive observation
Record detail In the YSL (8 mg/kg) + 5F–C12 (0.8 mg/kg) group, tumor inhibition increased markedly, reaching approximately 65.7% (Table S2).
- Measure
- percent_inhibition
- Value
- approximately 65.7%
- Target
- MCF-7
- Assay
- Not reported by source
AnticancerAntibacterialPositive observation
Record detail mice treated with YSL (8 mg/kg) combined with a higher dose of 5F–C12 (1.6 mg/kg) exhibited an even more pronounced tumor growth inhibition of 81.1% (Figure 6b,d).
- Measure
- percent_inhibition
- Value
- 81.1%
- Target
- MCF-7
- Assay
- Not reported by source
Local peptide labels such as P1, PEP1, or peptide 1 are grouped only within this paper and are not assumed to represent the same molecule across publications.